Back

Minnesota

Minnesota has strong shield laws (PDF, opens in a new tab) to help protect reproductive and gender-affirming health care provided to patients physically within the state.

Minnesota should further strengthen its protections for providers, helpers, and patients by focusing on these policy priorities:

01

Explicitly Protect Telehealth Care Regardless of Patient Location

02

Protect Provider Privacy on Medication Labels

03

Protect Against State Misbranding Actions

01

Explicitly Protect Telehealth Care Regardless of Patient Location

Telehealth provides a critical access point for people unable to travel to receive care or living in states with restrictions on abortion and gender-affirming care. Telehealth abortion care delivered by shield state providers accounts for close to 100% (opens in a new tab) of abortions accessed by people living in states where abortion is banned. A single telehealth provider can ensure access to time-sensitive health care for countless abortion and gender-affirming care patients each month. Currently, eight shield law states explicitly protect provision of care regardless of patient location, which includes telehealth care. By joining these eight states in enacting shield laws that explicitly apply regardless of patient location, Minnesota would offer its providers the strongest protections for offering care through telehealth, including to out-of-state patients. Minnesota should make this policy a priority in 2027.

02

Protect Provider Privacy on Medication Labels

Providers in shield law states care for abortion seekers from states where the provision of care is criminalized, as well as abortion seekers living in unsafe homes or who are subject to increased surveillance by law enforcement, immigration enforcement, or family regulation systems. Anti-abortion extremists in Louisiana and Texas have brought legal actions against telehealth shield providers claiming they discovered their names on a medication abortion pill label. Allowing providers to remove their names from medication abortion pill labels helps providers offer care privately and with less fear of detection and legal jeopardy. Minnesota should make this policy a priority in 2027.

03

Protect Against State Misbranding Actions

Despite decades of scientific evidence conclusively demonstrating the safety and effectiveness of mifepristone and other drugs commonly used for medication abortion, the anti-abortion movement has aggressively targeted (opens in a new tab) these medications, including by demanding FDA revoke approval of mifepristone, which was granted more than 25 years ago. Anti-abortion extremists have also demanded that unnecessary and burdensome restrictions be placed on mifepristone, including requiring it to be dispensed in person. Some shield law states have enacted (opens in a new tab) laws designed to protect against claims of misbranding under state law in the event FDA takes action affecting the approval or regulation of mifepristone or other safe and effective drugs used for medication abortion. Minnesota should make this policy a priority in 2027.

Opens your browser's print dialog. Choose Save as PDF.